Platelet and Thrombosis Research

Platelet and Thrombosis Research (PTR) is a specialized clinical research organization and laboratory focused on the study of platelet function and antithrombotic pharmacology. Led by Dr. Paul A. Gurbel, a pioneer in the field of interventional cardiology, the organization provides high-complexity platelet function testing and conducts clinical trials for major pharmaceutical companies developing antiplatelet and anticoagulant therapies. PTR is globally recognized for its expertise in personalized antiplatelet therapy and has been instrumental in the clinical development and regulatory approval of several blockbuster cardiovascular drugs, including clopidogrel and ticagrelor. The company operates advanced core laboratories that support Phase I-IV clinical trials with a focus on pharmacodynamics, pharmacokinetics, and the assessment of thrombotic risk. PTR serves as a critical partner for the pharmaceutical industry in optimizing dosing and evaluating the efficacy of next-generation blood thinners.